ESMO 2024 News & Programme
Refine Search
Biotechnology
Japan's Eisai has released data showing a statistically significant improvement in overall survival for patients taking part in the Phase III SELECT trial of tyrosine kinase inhibitor Lenvima. 29 August 2017
Biotechnology
In March 2016, Barack Obama became the first US President to visit Cuba since 1928, marking one of the final stages in a progressive thaw in relations that, it was hoped, would usher in a new era of trade and cooperation between the two countries. 7 August 2017
Biosimilars
The human epidermal growth factor receptor type 2 (HER2)-positive breast cancer space across the eight major markets of the USA, France, Germany, Italy, Spain, the UK, Japan and China is set to hit $9.89 billion in 2025, predicts a new report. 2 August 2017
Biotechnology
Norwegian non-Hodgkin’s Lymphoma specialist Nordic Nanovector has appointed a new head of medical affairs, Reza Safaei. 2 August 2017
Pharmaceutical
Merck & Co beat analyst predictions with its second quarter earnings, with soaring sales for the immuno-oncology drug Keytruda (pembrolizumab) proving crucial. 28 July 2017
Biotechnology
Merck & Co on Sunday presented results from two major studies of Keytruda (pembrolizumab), its anti-PD-1 therapy, in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology. 10 October 2016
Biotechnology
At the annual meeting of the European Society for Medical Oncology (ESMO) Congress, US pharma major Bristol-Myers Squibb on Sunday presented the final primary analysis of CheckMate -026, a trial investigating the use of Opdivo (nivolumab) monotherapy as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 ≥1%, which disappointed. 10 October 2016
Pharmaceutical
Presentations at the European Society for Medical Oncology (ESMO) Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer cachexia, a life-threatening wasting condition in cancer patients. Belgo-American drug developer iTeos Therapeutics announced mixed data at ESMO on its anti-TIGIT belrestotug, under development with UK pharma major GSK. Also of note, Germany’s BioNTech presented mid-stage at ESMO for its BNT327 in lung cancer. In other significant developments, Organon announced it is acquiring Roivant Sciences subsidiary Dermavant for up to $1.2 billion, but only $175 million upfront. Denmark’s Novo Nordisk released Phase IIa results for its recently-acquired obesity candidate monlunabant. 22 September 2024
Biotechnology
US biotech major Regeneron has shown that the addition of its investigational LAG-3 inhibitor fianlimab to its PD-1 inhibitor Libtayo (cemiplimab) offers impressive results in advanced melanoma. 17 September 2024
Biotechnology
A cancer drug in-licensed by German biotech major BioNTech from China-based Biotheus could be a good one, if mid-stage results shared at the European Society for Medical Oncology (ESMO) are anything to go by. 17 September 2024
Biotechnology
Eisai and Merck & Co have announced positive data for their combination therapy of Lenvima (lenvatinib) and Keytruda (pembrolizumab) in liver cancer. 17 September 2024
Biotechnology
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024 16 September 2024
Pharmaceutical
German pharma major Bayer today released results from the Phase III ARANOTE trial at the European Society for Medical Oncology (ESMO) taking place in Spain. 16 September 2024
Pharmaceutical
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024. 16 September 2024
Biotechnology
As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) at this year’s meeting of the European Society for Medical Oncology (ESMO). 16 September 2024
Biotechnology
Positive results from the NIAGARA Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically-significant and clinically-meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). 16 September 2024
Biotechnology
The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15, said US pharma giant Pfizer. 16 September 2024
Pharmaceutical
Pfizer released longer-term follow-up results from the Phase II single-arm PHAROS clinical trial evaluating the efficacy and safety of Braftovi (encorafenib) in combination with Mektovi (binimetinib) for patients with BRAF V600E - mutant metastatic non-small cell lung cancer (NSCLC). 16 September 2024
Biotechnology
Incyte has announced that its Phase III POD1UM-303/InterAACT2 trial met its primary endpoint of progression-free survival (PFS). 16 September 2024
Biotechnology
US pharma giant Merck & Co announced positive overall survival (OS) results from the final analysis of the Phase III KEYNOTE-811 trial. 14 September 2024
Pharmaceutical
As the world’s leading cancer research professionals arrived at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona on Friday, they were given a reminder of some of the remaining challenges that lie ahead in their field. 13 September 2024
Biotechnology
Among the first presentations at the European Society for Medical Oncology (ESMO) meeting that kicked off today, were results from the DESTINY-Breast12 Phase IIIb/IV trial of Enhertu (trastuzumab deruxtecan). 13 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Biotechnology
Tarlatamab demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial. 13 November 2023
Biotechnology
Germany’s BioNTech has presented positive Phase I/II on its CAR-T cell therapy candidate BNT211 in advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2023. 24 October 2023
Biotechnology
At the 2023 annual congress of the European Society of Medical Oncology (ESMO), Johnson & Johnson has presented important new data for Rybrevant (amivantamab-vmjw). 24 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze